Table 3 Changes in organ damage before and after the introduction of the MPZ group and the IVCY group
| Â | MPZ group | IVCY group | ||||||
|---|---|---|---|---|---|---|---|---|
0 M | 1 M | 3 M | 6 M | 0 M | 1 M | 3 M | 6 M | |
General symptoms | 6 (85.7%) | 0 | 0 | 0 | 11 (91.7%) | 0 | 0 | 0 |
Cutaneous manifestations | 5 (71.4%) | 1 (14.3%) | 0 | 0 | 8 (66.7%) | 4 (33.3%) | 1 (8.3%) | 0 |
ENT manifestations | 5 (71.4%) | 1 (14.3%) | 1 (14.3%) | 1 (14.3%) | 7 (58.3%) | 6 (50.0%) | 2 (16.7%) | 2 (16.7%) |
Heart manifestations | 1 (14.3%) | 1 (14.3%) | 0 | 0 | 2 (16.7%) | 0 | 0 | 0 |
Chest manifestations | 5 (71.4%) | 3 (42.9%) | 1 (14.3%) | 0 | 7 (58.3%) | 3 (25.0%) | 1 (8.3%) | 1 (8.3%) |
Abdominal manifestations | 1 (14.3%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Renal manifestations | 2 (28.6%) | 0 | 0 | 0 | 2 (16.7%) | 1 (8.3%) | 0 | 0 |
Sensor nervous system manifestations | 5 (71.4%) | 5 (71.4%) | 5 (71.4%) | 5 (71.4%) | 11 (91.7%) | 11 (91.7%) | 11 (91.7%) | 11 (91.7%) |
Motor nervous system manifestations | 2 (28.6%) | 2 (28.6%) | 2 (28.6%) | 2 (28.6%) | 6 (46.2%) | 6 (46.2%) | 6 (46.2%) | 6 (46.2%) |